GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Pantoprazole - oral delayed-release

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Protonix

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

PROTONIX (pantoprazole sodium) oral delayed-release products

Product / population
Adults; oral delayed-release formulations only.
Renal measure
Not specified; verify before use
Adult indication-specific doses

Erosive esophagitis associated with GERD: 40 mg once daily for up to 8 weeks; another 8-week course may be considered if unhealed. Maintenance of healing: 40 mg daily. Pathological hypersecretion, including Zollinger-Ellison syndrome: 40 mg twice daily, individualized as needed.

Renal evidence

The selected label reports similar pantoprazole pharmacokinetics in severe renal impairment and healthy subjects. This is not a source-specific numeric CrCl table or a newly verified dialysis protocol.

Source revision: | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08098cb2-c048-4640-f387-6beec4a38936

Scope: Source-read local summary; source-specific recommendations are not automatically interchangeable. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Handbook

Renal Drug Handbook, fifth edition

Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: See source.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePROTONIX (pantoprazole sodium) oral delayed-release productsRenal Drug Handbook, fifth edition
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08098cb2-c048-4640-f387-6beec4a38936

Product and population scope

PROTONIX oral delayed-release tablets or oral suspension. Intravenous preparation and infusion instructions are outside this product-specific page.

pantoprazole-oral:scope · Source section: Selected U.S. label: product title, route, dosage form and indicationRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

PROTONIX (pantoprazole sodium) oral delayed-release products

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adults; oral delayed-release formulations only.

Renal method: Not specified in this summary.
Source date:
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Adult indication-specific doses

Erosive esophagitis associated with GERD: 40 mg once daily for up to 8 weeks; another 8-week course may be considered if unhealed. Maintenance of healing: 40 mg daily. Pathological hypersecretion, including Zollinger-Ellison syndrome: 40 mg twice daily, individualized as needed.

pantoprazole-oral:dm-08098cb2-c048-4640-f387-6beec4a38936-1 · Source locator: 2.1, Table 1

Renal evidence

The selected label reports similar pantoprazole pharmacokinetics in severe renal impairment and healthy subjects. This is not a source-specific numeric CrCl table or a newly verified dialysis protocol.

pantoprazole-oral:dm-08098cb2-c048-4640-f387-6beec4a38936-2 · Source locator: 12.3, Patients with Renal Impairment

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08098cb2-c048-4640-f387-6beec4a38936
Retrieved
2026-09-05
Exact label title
PROTONIX (pantoprazole sodium) oral delayed-release products
DailyMed Set ID
08098cb2-c048-4640-f387-6beec4a38936
Labeler
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
DailyMed page updated
2026-05-18
FDA application
NDA marketing category
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
b458ffa1bc36628a69f4537fd15d335dbbcc9641e5c62c99fd5d46a6e0aacef7
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition

Open / share this exact local source

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Renal-function and dialysis summary

The book retains normal dosing at GFR 20-50, 10-20 and <10 mL/min and for APD/CAPD, HD, high-flux HDF and CAV/VVHD. Removal is described as absent for APD/CAPD and HD, and unknown for high-flux HDF and CAV/VVHD.

pantoprazole-oral:rdh5-766-1 · Source locator: Dose in renal impairment; Dose in renal replacement

Source-specific limits

The book covers both oral and IV products. This page is reconciled only to the selected U.S. oral delayed-release label; IV reconstitution, infusion and stability instructions were not transferred.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 766; PDF page 785
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
285c6dbe99363effd0fa1b6199cc6d67bcb0dbdee10e53e460b34f84b158d6ad

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08098cb2-c048-4640-f387-6beec4a38936
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
handbook us addition
Local text SHA-256
b568ef657d2cfa74a8c4ed32fb6abfb1c9554347543f6b0c6995d460ef0a1281
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report